Document Classification

Section Type: RESULTS

Text: Grade 3 or greater adverse events occurring in 5 % or more of patients in either treatment group were ascites (13 [5 %] of 277 patients treated with ramucirumab vs 11 [4 %] of 276 patients treated with placebo), hypertension (34 [12 %] vs ten [4 %]), asthenia (14 [5 %] vs five [2 %]), malignant neoplasm progression (18 [6 %] vs 11 [4 %]), increased aspartate aminotransferase concentration (15 [5 %] vs 23 [8 %]), thrombocytopenia (13 [5 %] vs one [< 1 %]), hyperbilirubinaemia (three [1 %] vs 13 [5 %]), and increased blood bilirubin (five [2 %] vs 14 [5 %]).